- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Pegvisomant – November 2016
Pegvisomant: Powder for injection 10 mg, Powder for injection 15 mg, Powder for injection 20 mg; Somavert®
Last updated
3 March 2017